FULC Fulcrum Tx Company Total Asset Base

Official company branding of Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics (FULC) revenues will be based on the implementation of advanced therapy methods for muscle pathologies and anemia. Current financial stability is limited by the trial stage, meaning cash flow stability depends on external funding. This chart illustrating the price evolution of the quotes on GURU.Markets shows total assets at 276.42, which is critical for a company occupying vacant niches in blood and muscle treatment with massive latent demand.

Fulcrum Tx - FULC Company Total Assets (period 07/04/2022 - 10/31/2026)

Financial and market metric breakdowns for Fulcrum Tx (FULC)

- price and consensus price forecast:
Stock Quotes fulcrumtx.com|FULC - Price Target Chart
- market capitalization data:
Market Capitalization Fulcrum Corp|FULC - Total Company Value
- shareholders' equity book value data:
Share Book Value Fulcrum Therapeutics|FULC - Book Capitalization|Market-to-Book Ratio fulcrumtx.com|FULC - Company Total Assets
- debt and liquidity details:
Total Debt to Equity Ratio Fulcrum Therapeutics|FULC - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Fulcrum Corp|FULC - Company Aggregate Debts|Debts to Book Capitalization Fulcrum Corp|FULC - Company Long-Term Debt|Company Short-Term Debt Fulcrum Therapeutics|Interim Coverage Ratio fulcrumtx.com
- financial results and valuation multiples details:
FULC - Net Income
Fundamental valuation:Fulcrum Therapeutics
Core merchandise of Fulcrum Therapeutics

Investors must find a balance between operational returns and the risks associated with leverage. For Fulcrum Therapeutics (FULC), developing specialized logistics for the delivery of rare disease therapies requires significant resource investments. An analysis of fluctuations in total capital and liabilities, reverse-calculated via ROA using market quotes, reflects the expansion of the asset base. The positive trajectory of this indicator confirms the growth of business scale and its overall financial stability.

Main competitors

Cumulative Company Assets vrtx.com|Aggregate Company Assets Alnylam|Insmed Inc. (INSM) - Company Total Asset Base|Aggregate Company Assets United Therapeutics Corp. (UTHR)|BMRN: Total Asset Value of Company|Company Total Assets BBIO (BridgeBio Pharma, Inc.)|BGM Group Limited (BGM) - Company Assets|Cogent Biosciences, Inc. - Company Total Assets|Xeris Biopharma Holdings, Inc. (XERS) - Cumulative Company Assets|KROS: Company Total Assets|ARCT - Company Total Asset Base|ETON (Eton Pharmaceuticals) - Company Total Assets|Company Total Assets kamada.com|Aggregate Company Assets Abeona Therapeutics (ABEO)|Aggregate Company Assets MREO (mereobiopharma.com)|Company Total Assets PLX (Protalix)|Company Total Asset Base Pliant Therapeutics Inc (PLRX)|APLT: Cumulative Company Assets|Total Asset Value of Company RNTX|GELS: Company Total Assets|Company Assets Aytu BioPharma (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Company Total Assets|Total Business Assets SRXH (SRx Health)|Cumulative Company Assets PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Aggregate Asset Value|Aggregate Company Assets Cyclo Therapeutics, Inc. CYTH|INZY (Inozyme Pharma Inc.) - Total Asset Value of Company|Reneo Pharma - Company Total Assets|Aggregate Asset Value CSCI (COSCIENS Bio)